Clinical Trial Update: AMG 172 First in Human Study in Patients With Kidney Cancer [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 trial of AMG 172 in patients with kidney cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• AMG 172 (AMG-172)

Snippet

Sponsor: Amgen | Conditions: Renal Cell Adenocarcinoma, Clear Cell Renal Carcinoma | Phase 1 | Status: COMPLETED